Consano Clinical Research

Executive Summary

Consano Clinical Research is a privately-held clinical research organization (CRO) based in Portland, Oregon, founded in 2012. The company specializes in conducting clinical trials for biopharmaceutical and medical device sponsors, with a particular emphasis on digital health integration. Consano's mission is to improve patient healing through innovative research, prioritizing patient safety, data security, and ethical practices. While the company has maintained a low public profile, its focus on digital health positions it favorably in a rapidly evolving landscape where decentralized and technology-enabled trials are gaining traction. As a small CRO, Consano likely competes on service quality and niche expertise rather than scale, and it may benefit from the growing outsourcing trend among sponsors seeking specialized partners. Looking ahead, Consano's growth prospects hinge on winning new contracts, expanding its digital health capabilities, and possibly forming strategic alliances. The company operates in a competitive but growing market, with the global CRO market expected to continue expanding. However, its private nature and lack of disclosed financials make it challenging to assess its market position or trajectory. The company's engagement with biopharmguy lists suggests it is actively seeking visibility among sponsors. With a limited track record of public milestones, near-term catalysts are likely to revolve around operational achievements such as trial initiations or technology enhancements. Overall, Consano represents a small but potentially resilient player in the clinical research space, with upside tied to its ability to differentiate through digital innovation.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a new clinical trial contract with a biopharma sponsor60% success
• TBDLaunch of a digital health platform or partnership to enhance decentralized trial capabilities40% success
• Q2 2026Achievement of a key operational milestone (e.g., enrollment target or study completion)70% success